Sponsor or institution
Clinical trials and research at Jiangsu HengRui Medicine Co., Ltd.
As of November 12, 2026, Find a Trial lists 55 clinical trials run by Jiangsu HengRui Medicine Co., Ltd. that are recruiting, at sites in 13 countries (most in China (54), Australia (2), South Korea (2)). By phase: Phase 1/2 (16), Phase 3 (14), Phase 2 (12), Phase 1 (12). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 55Clinical trials
- 13Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| HRS-7172 with other cancer drugs in advanced pancreatic cancer | Phase 1/2 | Shanghai, Shanghai Municipality | Recruiting | Sep 8, 2026 |
| FH-006 vs physician's choice chemotherapy for ESCC after PD-1/PD-L1 + platinum failure | Phase 3 | Jinan, Shandong | Recruiting | Aug 27, 2026 |
| HRS-9190 vs Rocuronium for Muscle Relaxation During Anesthesia | Phase 3 | Changsha, Hunan and 1 other locations | Recruiting | Aug 5, 2026 |
| HRS-7525 tablets in advanced prostate cancer | Phase 1 | Sydney, New South Wales and 6 other locations | Recruiting | Jul 17, 2026 |
| HRS-3005 in B-cell Malignancies | Phase 1 | Tianjin, Tianjin Municipality | Recruiting | Apr 29, 2026 |
| Trastuzumab Rezetecan versus Trastuzumab Deruxtecan for unresectable HER2‑low, HR‑positive breast cancer | Phase 2 | Beijing, Beijing Municipality | Recruiting | Mar 27, 2026 |
| Comparing bioavailability and safety of different SHR-3167 injection formulations | Phase 1 | Changsha, Hunan | Recruiting | Mar 24, 2026 |
| HRS-8364 treatment for advanced solid tumors | Phase 1/2 | Guangzhou, Guangdong and 1 other locations | Recruiting | Mar 3, 2026 |
| SHR-4394 combined with anti-tumor therapy for prostate cancer | Phase 1/2 | Chengdu, Sichuan and 1 other locations | Recruiting | Feb 12, 2026 |
| SHR-1049 for people with advanced solid tumors | Phase 1 | Hangzhou, Zhejiang | Recruiting | Feb 2, 2026 |
All recruiting trials (55)
-
HRS-7172 with other cancer drugs in advanced pancreatic cancer
This study tests if HRS-7172 added to standard cancer therapies can help people with advanced pancreatic cancer that has RAS mutations or amplifications.
-
FH-006 vs physician's choice chemotherapy for ESCC after PD-1/PD-L1 + platinum failure
This study tests whether FH-006 helps people with esophageal squamous cell carcinoma live longer than the physician’s choice second-line chemotherapy after prior PD-1/PD-L1 inhibitors with platinum have stopped working.
-
HRS-9190 vs Rocuronium for Muscle Relaxation During Anesthesia
This Phase 3 trial tests whether HRS-9190 can provide effective muscle relaxation for intubation and surgery as compared with rocuronium in adults undergoing elective general anesthesia.
-
HRS-7525 tablets in advanced prostate cancer
This study tests whether HRS-7525 tablets can be safely given to men with advanced prostate cancer and helps find a tolerable dose for future tests.
-
HRS-3005 in B-cell Malignancies
This early-phase study tests HRS-3005 in adults with relapsed or refractory B-cell cancers to see if it is safe and tolerable and to find a suitable dose for future studies.
-
Trastuzumab Rezetecan versus Trastuzumab Deruxtecan for unresectable HER2‑low, HR‑positive breast cancer
This Phase 2 trial tests different doses of Trastuzumab Rezetecan compared with Trastuzumab Deruxtecan in women with HR-positive, HER2-low unresectable locally recurrent or metastatic breast cancer to see which dose is safer and more effective.
-
Comparing bioavailability and safety of different SHR-3167 injection formulations
This trial will test how different formulations of the SHR-3167 injection are absorbed and whether they are safe in healthy adults aged 18–55.
-
HRS-8364 treatment for advanced solid tumors
This will test HRS-8364 tablets to see if they help adults aged 18–75 with advanced solid tumors who have not responded to or cannot tolerate standard treatments.
-
SHR-4394 combined with anti-tumor therapy for prostate cancer
This trial tests whether adding SHR-4394 to other anti-cancer treatments is safe and can lower PSA in men with metastatic prostate cancer.
-
SHR-1049 for people with advanced solid tumors
This trial tests a drug called SHR-1049 to see if it is safe, how the body handles it, and whether it helps adults 18–75 with advanced or metastatic solid tumors who have no effective standard treatments left.
-
SHR4640 plus 40 mg febuxostat for primary gout and high uric acid
This trial will test whether adding SHR4640 to a daily 40 mg febuxostat pill lowers uric acid in adults with primary gout who still have high uric acid on 40 mg febuxostat.
-
HRS-4357 versus novel androgen receptor pathway inhibitors for PSMA-positive metastatic castration-resistant prostate cancer
This trial will test whether HRS-4357 works better than newer androgen receptor pathway drugs (like enzalutamide or abiraterone) for men with PSMA-positive metastatic castration-resistant prostate cancer.
-
Hetrombopag versus placebo for chemotherapy-related low platelets
This trial tests whether hetrombopag tablets can raise platelet counts and reduce bleeding in adults who develop low platelets from platinum- or gemcitabine-based chemotherapy.
-
SHR0302 tablets with or without SHR0302 base gel for non-segmental vitiligo
This trial will test whether SHR0302 tablets, alone or together with an SHR0302 base gel, help adults with non-segmental vitiligo and are safe to use.
-
FH-006 combined with other anticancer therapies for lung cancer
This study will see if giving FH-006 together with other anti-cancer drugs is safe and shows early benefit for people with advanced non-small cell lung cancer.
-
Rezvilutamide versus enzalutamide for low-volume metastatic hormone-sensitive prostate cancer
This Phase III trial tests whether rezvilutamide works as well as or better than enzalutamide for men with low-volume metastatic hormone-sensitive prostate cancer who are receiving androgen-deprivation therapy.
-
Liposomal irinotecan plus oxaliplatin and 5‑FU/LV versus nab‑paclitaxel plus gemcitabine for first‑line metastatic pancreatic cancer
This study tests whether a liposomal irinotecan combination (with oxaliplatin and 5‑FU/LV) works better than nab‑paclitaxel plus gemcitabine as first‑line treatment for people with metastatic pancreatic cancer.
-
HRS-4642 plus AG vs AG alone in first-line advanced pancreatic cancer with KRAS G12D mutation
This trial tests whether adding HRS-4642 to AG therapy helps people with KRAS G12D‑mutant advanced or metastatic pancreatic cancer in their first-line treatment.
-
HRS-4508 combined with other antitumor therapies for locally advanced or metastatic non-small cell lung cancer.
This test will try HRS-4508 together with other cancer treatments to see if it helps people with locally advanced or metastatic non-small cell lung cancer.
-
SHR3680, HS-20093, and SHR2554 combined with hormonal therapy for advanced prostate cancer
This trial will test whether adding HS-20093 or SHR2554 to a novel hormonal agent helps men with advanced prostate cancer better control their disease while continuing standard androgen-deprivation therapy.
-
HRS-2329 for advanced solid tumors with RAS mutations or amplifications
This trial will test the oral drug HRS-2329 in adults with advanced solid tumors that have RAS mutations or amplifications who have not responded to standard treatments.
-
SHR2554 combined with other cancer drugs for advanced non-small cell lung cancer
This study tests whether SHR2554 tablets given with other anti-cancer treatments are safe and can shrink tumors in adults with locally advanced or metastatic non-small cell lung cancer.
-
HRS-7172 for advanced solid tumors with RAS mutations or amplifications
This study will try an experimental oral drug called HRS-7172 in adults with advanced solid tumors that have RAS mutations or amplifications to see if it is safe and how the body handles it.
-
HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
This study tests whether HRS-4508 added to other cancer medicines helps people with solid tumors.
-
FH-006 injection study for advanced solid tumors
This study tests FH-006, alone and with SHR-1316 and paclitaxel, to see if it is safe and tolerable in adults with unresectable or metastatic solid tumors who have measurable disease.
-
Phase I testing of HRS-6093 for advanced solid tumors with KRAS G12D mutation
This Phase I study will test whether the experimental drug HRS-6093 is safe, tolerable, and how it behaves in the body for adults with advanced solid tumors that carry the KRAS G12D mutation.
-
SHR2554 combined with other cancer medicines for advanced stomach or gastroesophageal junction adenocarcinoma
This study will test if adding SHR2554 to other anti-cancer treatments helps people with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
-
HRS-6213 imaging in healthy volunteers and people with solid tumors
This study will test HRS-6213, a radioactive imaging agent, in healthy volunteers and people with solid tumors to check safety, radiation dose, how it moves through the body, and whether it shows tumors.
-
SHR-A1811 for HER2-positive recurrent or metastatic cervical cancer.
This trial tests SHR-A1811 in people with HER2-expressing recurrent or metastatic cervical cancer whose disease did not respond to prior systemic therapy.
-
SHR-3167 steady-state effects in adults with type 2 diabetes.
This test looks at how the new drug SHR-3167 behaves in the body and affects blood sugar control in adults with type 2 diabetes.
-
HRS-4508 for locally advanced or metastatic non-small cell lung cancer
This trial will test HRS-4508, an oral tablet, to see if it shrinks tumors or controls disease in adults with locally advanced or metastatic non-small cell lung cancer who have failed or cannot tolerate standard treatments.
-
HRS-6209 added to other treatments for breast cancer
This study will see if adding HRS-6209 to other breast cancer treatments is safe and can help control tumors in adults whose cancer has progressed.
-
Evaluating HRS-6768 for advanced solid tumors
This study is testing a new drug called HRS-6768 to see if it can help people with advanced solid tumors who haven't had success with other treatments.
-
Evaluating SHR-A1811 for Ovarian Cancer Treatment
This study is testing if a new drug called SHR-A1811 can help improve treatment for people with ovarian cancer when used alongside standard chemotherapy.
-
Evaluating SHR-4394 Injection for Prostate Cancer
This study is testing a new injection called SHR-4394 to see if it is safe and effective for men with advanced prostate cancer who haven't responded to other treatments.
-
Evaluating RSS0343 Tablets for Non-cystic Fibrosis Bronchiectasis
This study is testing if RSS0343 tablets can improve lung function and health in adults with non-cystic fibrosis bronchiectasis.
-
Testing FH-006 injection in patients with advanced solid tumors
This study is testing a new injection called FH-006 to see if it can help people with advanced solid tumors who have run out of other treatment options.
-
Treatment for metastatic prostate cancer using HRS-1167 with other medications
This study is testing if a new drug called HRS-1167, when taken with other medications, can safely help men with metastatic prostate cancer.
-
HRS-4508 as a first-in-human treatment in advanced solid tumors
This study tests whether HRS-4508 can be safely given and show early signs of benefit in adults with advanced or metastatic solid tumors who have exhausted standard treatments.
-
HRS-5041 tablets combined with antitumor therapy for advanced prostate cancer
This study is testing if adding HRS-5041 tablets to standard treatments can help people with advanced prostate cancer feel better and stay safe during their therapy.
-
Evaluating HRS-6209 with other treatments for advanced breast cancer
This study is testing a new drug called HRS-6209 combined with other treatments to see if it helps women with advanced breast cancer that hasn’t responded to previous therapies.
-
Bupivacaine liposome injection for pain after single-port thoracoscopic lobectomy
This test will try a long-acting bupivacaine liposome injection given as a paravertebral nerve block to reduce pain after single-port thoracoscopic lobectomy in adults.
-
HRS-4642 combined with antineoplastic drugs for advanced KRAS G12D solid tumors
This trial will test whether adding HRS-4642 to standard anti-cancer drugs is safe and shows early signs of benefit in adults with advanced solid tumors that have a KRAS G12D mutation.
-
Treatment of advanced lung cancer with HER2 mutations using SHR-A1811
This study is testing a new treatment called SHR-A1811 to see if it works better than standard care for adults with advanced lung cancer that has specific HER2 mutations.
-
Using bupivacaine liposome injection for pain relief in children during orthopedic surgery
This study is testing if a special pain relief injection can help children aged 6 to 17 feel better after orthopedic surgery.
-
Treatment for HER2-positive gastric cancer after first-line therapy
This study is testing a new treatment called SHR-A1811 to see if it can help people with HER2-positive gastric cancer who haven't improved after their first treatment.
-
Treatment of T-cell lymphoma with SHR2554
This study is testing a new drug called SHR2554 to see if it works better than Chidamide for adults with relapsed or hard-to-treat T-cell lymphoma.
-
Combining SHR-A1811 with other treatments for advanced solid tumors
This study is testing if a new treatment called SHR-A1811, when combined with other cancer therapies, can help people with advanced solid tumors that have HER2.
-
Testing HRS-5041 for advanced prostate cancer
This study is testing a new drug called HRS-5041 to see if it is safe and effective for men with advanced prostate cancer who haven't responded to other treatments.
-
Treatment for advanced gastrointestinal pancreatic neuroendocrine tumors using Lutetium (177Lu) Oxodotreotide Injection
This study is testing if a new injection can help people with advanced pancreatic neuroendocrine tumors feel better and live longer when combined with another medication.
-
Injectable SHR-A1811 with Pyrotinib or SHR-1316 for advanced lung cancer
This study is testing if a new injectable treatment called SHR-A1811, used with either Pyrotinib or SHR-1316, can help people with advanced lung cancer that has a specific marker called HER2.
-
Testing HRS-1167 for advanced solid tumors
This study is testing a new drug called HRS-1167 to see if it can help people with advanced solid tumors, like ovarian, breast, pancreatic, and prostate cancers, who haven't had success with other treatments.
-
Evaluating SHR-A1904 for advanced solid tumors
This study is testing a new treatment called SHR-A1904 to see if it is safe and effective for people with advanced solid tumors who have few other options.
-
Camrelizumab plus apatinib for advanced gastric and gastroesophageal junction adenocarcinoma
This trial tests whether combining camrelizumab and apatinib can help people with advanced gastric or gastroesophageal junction cancer that progressed after first-line platinum-based therapy, especially if their tumors are PD-L1 positive.
-
Combination of SHR-1316 and chemotherapy for resectable lung cancer
This study tests whether adding a new antibody called SHR-1316 to standard chemotherapy can help people with early-stage lung cancer feel better and improve their treatment results.
Quick answers
How many clinical trials run by Jiangsu HengRui Medicine Co., Ltd. are recruiting right now?
55, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 13 countries. The most sites are in China (54 trials), Australia (2 trials), South Korea (2 trials), United States (2 trials), Moldova (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 16, Phase 3: 14, Phase 2: 12, Phase 1: 12. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.